Table 1.
Baseline Demographics | ||||
---|---|---|---|---|
C4d+ AR (n=5) | C4d− AR (n=5) | STA (n=5) | P value | |
Recipient | ||||
Gender, %females | 20% | 40% | 20% | 0.71 |
Mean age (yr) | 12.0 ± 2.2 | 13.3 ± 2.7 | 8.7 ± 2.9 | 0.47 |
Immunosuppression, %SF# | 100% | 100% | 100% | 1 |
Post-txp sampling (mo) | 37.1 ± 10.5 | 12.4 ± 4.7 | 28.0 ± 9.9 | 0.17 |
Race* | 40%, 20%, 0%, 20%, 20% | 80%, 20%, 0%, 0%, 0% | 20%, 20%, 20%, 20%, 20% | 0.65 |
Cause of ESRD** | 20%, 0%, 20%, 60%, 0%, 0% | 0%, 40%, 20%, 20%, 20%, 0% | 40%, 20%, 20%, 20%, 0%, 0% | 0.47 |
Mean HLA match | 2.0 ± 0.4 | 3.0 ± 0.6 | 3.8 ± 0.9 | 0.3 |
PRA <20% | 100% | 100% | 100% | 1 |
Donor | ||||
Type, %LD | 80% | 40% | 100% | 0.23 |
Gender, %females | 40% | 40% | 80% | 0.34 |
Mean age, yr | 31.2 ± 5.3 | 37.7 ± 5.8 | 34.8 ± 3.4 | 0.65 |
SF: Steroid-free immunosuppression treatment (ref), consisting of daclizumab induction + mycophenolate mofetil + tacrolimus
Race: 1=Caucasian; 2= Hispanic; 3=Asian; 4=African American; 5=Other
ESRD= End-stage Renal Disease: ESRD categories: 1= Glomerulonephritis; 2= Polycystic Kidney Disease; 3=Dysplasia; 4=Reflux Nephropathy; 5=Obstructive Uropathy; 6=Other